Drug Profile


Latest Information Update: 10 Oct 2003

Price : $50

At a glance

  • Originator Fidia Farmaceutici; Georgetown University School of Medicine
  • Developer Nonindustrial source
  • Class Antidementias; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Excitatory amino acid antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Dementia; Epilepsy; Parkinson's disease

Most Recent Events

  • 10 Oct 2003 Discontinued for Parkinson's disease in USA (unspecified route)
  • 10 Oct 2003 Discontinued - Preclinical for Dementia in USA (unspecified route)
  • 10 Oct 2003 Discontinued for Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top